Shares of AbbVie Inc. (NYSE: ABBV) touched a fresh 52-week high on Monday, capping a 34% gain over the past 12 months and outperforming the S&P 500 by a wide margin year to date. The latest rally was catalyzed by the drugmaker’s $10.9 billion all-cash acquisition of immunology biotech Apogee Therapeutics (NASDAQ: APGE), a deal that has deepened debate over whether the stock remains a compelling buy at current levels.
Even after its recent run-up, AbbVie trades at less than 18 times forward earnings based on analyst consensus, a notable discount to the S&P 500’s average multiple of 21.
Large-cap pharma stocks broadly faced valuation pressure earlier this year amid U.S. healthcare policy reform concerns, but AbbVie has steadily unwound that discount through consistent earnings beats. The company reported $15 billion in first-quarter revenue, up 12% year over year, with adjusted earnings per share of $2.65 — a 7% increase from the prior-year period. It also raised its full-year 2026 adjusted EPS guidance to a range of $14.08 to $14.28, representing 41.8% growth at the midpoint.
A Dividend King with 54 consecutive years of payout increases (including its tenure under Abbott Laboratories), AbbVie currently yields roughly 2.9%, bolstering its appeal as a defensive blue-chip holding in volatile markets.
The June 22 deal to acquire Apogee — priced at $135.11 per share, a 49% premium to the biotech’s prior close — marks AbbVie’s latest push to cement its dominance in immunology. The transaction, approved by both boards, is expected to close in the third quarter of 2026, subject to regulatory clearance and shareholder votes.
AbbVie has already successfully transitioned its core immunology franchise from legacy blockbuster Humira to next-generation therapies Skyrizi and Rinvoq. The Apogee buy adds zumilokibart, a long-acting IL-13 antibody targeting moderate-to-severe atopic dermatitis and asthma. Unlike market leader Dupixent — which generated nearly $18 billion in annual sales and requires biweekly dosing — zumilokibart is dosed once every three to six months thanks to its extended-half-life engineering, offering a meaningful convenience advantage. Phase 2 data showed roughly two-thirds of patients achieved significant skin clearance after 16 weeks of treatment, positioning the drug as a potential $10 billion-plus peak seller if late-stage trials succeed.
Apogee’s pipeline also includes combination therapies APG273 (for asthma and COPD) and APG279 (for atopic dermatitis), both targeting IL-13 and TSLP pathways to further complement AbbVie’s existing portfolio. Notably, the deal is funded entirely with operating cash flow with no share dilution, and AbbVie’s track record of integrating large acquisitions — including Allergan and ImmunoGen — adds confidence in its ability to commercialize the assets.
Still, the acquisition carries meaningful uncertainty. Zumilokibart remains in clinical development, with inherent risks of late-stage trial failures or regulatory delays. AbbVie has said the deal will not be accretive to adjusted EPS until 2032 at the earliest, locking up billions in capital across a six-year horizon. Setbacks faced by the Cerevel Therapeutics pipeline, another acquired asset, serve as a reminder of the execution risks embedded in biotech M&A.
In the near term, much of the deal’s optimism may already be priced in following the run to 52-week highs, leaving the stock vulnerable to pullbacks. Any disappointment in upcoming clinical readouts or earnings guidance could trigger a retreat from current elevated levels.
For long-term investors, AbbVie’s core thesis remains intact: a durable earnings base, below-market valuation, expanding pipeline, and a steadily growing dividend. The stock continues to offer attractive value for buy-and-hold investors prioritizing steady growth and income. For traders with a shorter time horizon, however, stretched near-term sentiment and clinical development volatility warrant caution.
